After Today’s Significant Increase, Is Vanda Pharmaceuticals Inc. (VNDA)’s Near-Term Analysis Positive?

September 17, 2017 - By Louis Casey

Investors sentiment decreased to 1.29 in Q4 2016. Its down 1.10, from 2.39 in 2016Q3. It dived, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 46 reduced holdings. 20 funds opened positions while 55 raised stakes. 39.66 million shares or 1.45% less from 40.25 million shares in 2016Q3 were reported.
New York-based Jpmorgan Chase & has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Dekabank Deutsche Girozentrale reported 0% stake. One Trading L P reported 6,255 shares. Pnc Group Inc reported 282,292 shares stake. Venbio Select Advisor Lc owns 381,466 shares. Sei Invests holds 816 shares. Creative Planning has invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Blackrock Institutional Na has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). State Board Of Administration Of Florida Retirement reported 107,768 shares. Cornerstone Capital Management Holdings Ltd Llc accumulated 0.02% or 148,900 shares. Shell Asset Mngmt owns 33,028 shares. Walleye Trading Ltd Liability Company reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 52,000 were accumulated by Cheyne Capital Mgmt (Uk) Ltd Liability Partnership. Blackrock Inc stated it has 9,396 shares or 0% of all its holdings. Ridgeworth Mgmt Limited Liability Company, a Georgia-based fund reported 38,960 shares.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 4.25% or $0.75 on September 15, reaching $18.4. About 2.04M shares traded or 240.41% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since September 17, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 8 months positive chart setup for the $825.39 million company. It was reported on Sep, 17 by Barchart.com. We have $20.06 PT which if reached, will make NASDAQ:VNDA worth $74.29 million more.

Wall Street await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to release earnings on November, 1. Analysts forecast EPS of $-0.10, down exactly $0.16 or 266.67 % from 2014’s $0.06 EPS. After posting $-0.03 EPS for the previous quarter, Vanda Pharmaceuticals Inc.’s analysts now forecast 233.33 % negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 16 analyst reports since September 2, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 2 by Piper Jaffray. The firm earned “Buy” rating on Wednesday, October 21 by Brean Capital. Piper Jaffray initiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Tuesday, June 27 with “Buy” rating. The rating was maintained by H.C. Wainwright on Thursday, August 3 with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Thursday, August 3 report. The firm has “Buy” rating given on Wednesday, November 9 by Aegis Capital. As per Wednesday, March 9, the company rating was maintained by JMP Securities. JMP Securities maintained the shares of VNDA in report on Friday, August 26 with “Market Outperform” rating. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Thursday, October 6. Oppenheimer maintained it with “Buy” rating and $2100 target in Thursday, August 3 report.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Prnewswire.com which released: “Vanda Pharmaceuticals Announces Participation at September 2017 Investor …” on September 11, 2017, also Zacks.com with their article: “Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA …” published on August 29, 2017, Seekingalpha.com published: “Vanda Pharmaceuticals: An Early Stage Bioscience Consideration” on July 26, 2017. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech …” published on September 06, 2017 as well as Seekingalpha.com‘s news article titled: “Vanda Pharmaceuticals Keeps Chugging Along” with publication date: June 26, 2017.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $825.39 million. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ , Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.